CC BY-NC-ND 4.0 · Endosc Int Open 2018; 06(11): E1283-E1288
DOI: 10.1055/a-0684-9638
Case report
Owner and Copyright © Georg Thieme Verlag KG 2018

Recurrent esophagogastric variceal bleeding due to portal vein thrombosis caused by protein S deficiency

Haoxiong Zhou
Department of Gastroenterology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
,
Jieying Xuan
Department of Gastroenterology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
,
Xianyi Lin
Department of Gastroenterology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
,
Yunwei Guo
Department of Gastroenterology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
› Author Affiliations
Further Information

Publication History

submitted 13 March 2018

accepted after revision 30 May 2018

Publication Date:
07 November 2018 (online)

Abstract

Background and study aims Esophagogastric variceal bleeding (EGVB) is common in patients with portal vein thrombosis (PVT). Hereditary deficiencies in natural anticoagulant proteins, such as protein S, might contribute to PVT. However, recurrent EGVB caused by PVT in patients with protein S deficiency is seldom reported. Herein, we present the case of a 38-year-old man with protein S deficiency complicated with PVT. The patient suffered recurrent EGVB for 7 years. He underwent splenectomy plus pericardial revascularization and sequential endoscopic therapy, including one gastric variceal obturation (GVO) procedure and two esophageal variceal ligations (EVL) to eradicate the varices. Rivaroxaban was administrated to reduce risk of thrombotic events. The patient is currently well without rebleeding after 1 year of follow-up. To our knowledge there is no consensus on management of recurrent EGVB on the basis of thrombophilia complicated with PVT. According to our practice, sequential endoscopic therapy combined with anticoagulant appears to be effective and safe.

 
  • References

  • 1 Lipe B, Ornstein DL. Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin. Circulation 2011; 124: e365-e368
  • 2 Hwang S, Kim DY, Kim M. et al. Deficiencies in proteins C and S in a patient with idiopathic portal hypertension accompanied by portal vein thrombosis. Korean J Hepatol 2010; 16: 176-181
  • 3 Chirinos VJA, Muñoz GR, Amo PM. et al. Portal and mesenteric thrombosis associated with protein S deficiency. Rev Esp Enferm Dig 2008; 100: 104-107
  • 4 Dykes AC, Walker ID, McMahon AD. et al. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113: 636-636
  • 5 ten Kate MK, van der Meer J. Protein S deficiency: a clinical perspective. Haemophilia 2008; 14: 1222-1228
  • 6 Primignani M, Martinelli I, Bucciarelli P. et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005; 41: 603-608
  • 7 Denninger MH, Chaït Y, Casadevall N. et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587-591
  • 8 Condat B, Pessione F, Hillaire S. et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120: 490-497
  • 9 Noronha FC, Seijo S, Plessier A. et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology 2016; 63: 1640-1650
  • 10 Su AP, Zhang ZD, Tian BL. et al. Transjugular intrahepatic portosystemic shunt versus open splenectomy and esophagogastric devascularization for portal hypertension with recurrent variceal bleeding. Hepatobiliary Pancreat Dis Int 2017; 16: 169-175
  • 11 Ellison EC, Fabri PJ. Complications of splenectomy. Etiology, prevention, and management. Surg Clin North Am 1983; 63: 1313-1330
  • 12 Nery F, Valadares D, Morais S. et al. Efficacy and safety of direct-acting oral anticoagulants use in acute portal vein thrombosis unrelated to cirrhosis. Gastroenterology Res 2017; 10: 141-143
  • 13 De Gottardi A, Trebicka J, Klinger C. et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int 2017; 37: 694-699
  • 14 van der Hulle T, Kooiman J, den Exter PL. et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12: 320-328
  • 15 Skelley JW, White CW, Thomason AR. The use of direct oral anticoagulants in inherited thrombophilia. J Thromb Thrombolysis 2017; 43: 24-30
  • 16 Spaander MC, Darwish MS, van Buuren HR. et al. Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. Gastrointest Endosc 2008; 67: 821-827